Here is the rundown on market activity for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Yesterday Director Lewis Clayton Jr. Cantley disclosed the sale of 2,504 shares. The shares sold for $54.08. The Director now owns $5,898,397 of the stock per the Form 4 SEC filing. Scott Biller, Chief Scientific Officer disclosed the sale of 5,000 shares of (AGIO). The shares were sold on September 20th for an average price of $50.00. Biller now owns $1,050,000 of the stock according to the SEC filing.
These firms have also modified their investment in AGIO. As of quarter end Northwestern Mutual Wealth Management Co had disposed of a total of 7 shares trimming its position 13.2%. The value of the company’s investment in Agios Pharmaceuticals, Inc. went from $2,000 to $2,000 a change of 0.0% quarter over quarter. As of the end of the quarter Royal Bank Of Canada had sold 15 shares trimming its holdings by 75.0%. The value of the investment in AGIO decreased from $1,000 to $0 a change of $1,000 quarter to quarter.
As of the end of the quarter Schwab Charles Investment Management Inc had bought 1,072 shares growing its stake by 2.0%. The value of the investment in (AGIO) decreased from $3,412,000 to $2,247,000 decreasing 34.1% since the last quarter. As of the end of the quarter Metropolitan Life Insurance Co/ny had bought a total of 197 shares growing its position 10.2%. The value in dollars increased from $79,000 to $89,000 a change of 12.7% for the reporting period.
BTIG Research initiated coverage on the stock by announcing an initial rating of “Neutral”. On June 13 the stock rating was upgraded from “Neutral” to “Buy” in a report issued by JP Morgan.
On June 13, 2016 the stock rating was changed to a “Buy” in a report from Canaccord Genuity a boost from the previous “Hold” rating. May 18 investment analysts at Credit Suisse made no change to the company rating of “Outperform” and moved down the price target to $70.00 from $75.00.
On March 30 analysts at SunTrust Robinson Humphrey started coverage setting a rating of “Buy” and projecting a price target of $57.00. Equity analyst Janney Capital issued its first research report on the stock giving it an initial rating of “Neutral”.
The company is down by -0.62% since yesterday’s close of $54.55. The stock last traded at $54.21 which is a tad above the 50 day moving average of $43.16 and which is just a bit higher than the 200 day moving average of $45.50. The 50 day moving average was up $11.05 and the 200 day average was up $8.71.
As of the last earnings report the EPS was $-4.24 and is projected to be $-5.04 for the current year with 38,046,000 shares now outstanding. Next quarter’s EPS is forecasted to be $-1.38 with next year’s EPS anticipated to be $-5.30.
Investors are a little more bullish on shares of Agios Pharmaceuticals, Inc. if you look at the motion in short interest. The firm experienced a fall in short interest of -0.06% as of September 15, 2016 from the last reporting period. Short shares decreased 358,851 over that timeframe. The days to cover decreased to 4.8 and the percentage of shorted shares is 0.16% as of September 15.